23andMe Holding Co. (ME) Tax Rate: 0.02%
Is 23andMe Holding Co.’s tax rate high or low?
23andMe Holding Co.'s tax rate of 0.02% is 95% below its 5-year average of 0.41%, near the low end of its 5-year range (-0.01%–1.57%).
300.00% above its 12-month average of 0.01%.
ME Tax Rate Chart
ME Average Tax Rate Chart
ME Current vs Average Tax Rate Chart
ME Tax Rate Metrics
TAX RATE
0.02%
TAX RATE AVG TTM
0.01%
TAX RATE AVG 3Y
0.62%
TAX RATE AVG 5Y
0.41%
TAX RATE AVG 10Y
N/A
TAX RATE AVG 15Y
N/A
TAX RATE AVG 20Y
N/A
CURRENT VS TTM AVG
+300.00%
CURRENT VS 3Y AVG
-96.75%
CURRENT VS 5Y AVG
-95.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
23andMe Holding Co. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Tax Rate FAQ
- What is the tax rate for 23andMe Holding Co. (ME)?
- The tax rate for ME stock is 0.02%.
- Is 23andMe Holding Co.'s tax rate high or low?
- 23andMe Holding Co.'s tax rate of 0.02% is 95% below its 5-year average of 0.41%, near the low end of its 5-year range (-0.01%–1.57%).
- What is the TTM average tax rate for 23andMe Holding Co. (ME)?
- The TTM average tax rate for ME stock is 0.01%.
- What is the 3Y average tax rate for 23andMe Holding Co. (ME)?
- The 3Y average tax rate for ME stock is 0.62%.
- What is the 5Y average tax rate for 23andMe Holding Co. (ME)?
- The 5Y average tax rate for ME stock is 0.41%.
23andMe Holding Co. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-03-31 | 0.02% |
| 2024-03-31 | -0.01% |
| 2023-03-31 | 0.88% |
| 2022-03-31 | 1.57% |
| 2021-03-31 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-03-31 | 0.00% |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage